Lanreotide on Collateral Response to Endothelin-1 and Vasopressin in Cirrhotic Rats

Background

Portosystemic collaterals in cirrhosis are often complicated with hemorrhage. Endothelin-1 (ET-1) and argi-nine vasopressin (AVP) have been shown to directly constrict collaterals of portal hypertensive rats. Furthermore, octreotide, a long-acting somatostatin analog, enhances ET-1-related collateral vasoconstriction if administered in the perfusate before ET-1 incubation. However, long-term effects of somatostatin analogs on collateral response to ET-1 and AVP remain unclarified. This study investigated the effects of lanreotide (a longer-acting somatostatin analog when compared with octreotide) on the portosystemic collateral vascular reactiveness to ET-1 and AVP in cirrhotic rats.

Methods

Liver cirrhosis was induced in Sprague-Dawley rats by common bile duct ligation (BDL). On the 33^rd day after BDL, rats received 1 intramuscular injection with lanreotide (10 mg/kg) or distilled water. On the 43^rd day after BDL, systemic, and portal hemodynamics were evaluated. By an in situ perfusion model, ET-1 (10⁻¹⁰ −10⁻⁷ mol/L) and AVP (10⁻¹⁰ −3 × 10⁻⁷ mol/L) were applied to assess the collateral responses.

Results

Heart rate, mean arterial pressure, and portal pressure were not modified by lanreotide. Lanreotide pretreat-ment enhanced collateral vascular response to ET-1 and reached statistical significance at 10⁻⁷ mol/L without inducing changes to AVP.

Conclusion

Lanreotide augmented the collateral vascular responsiveness to ET-1 but not to AVP in cirrhotic rats.

Key Words:  endothelin-1 , lanreotide , liver cirrhosis , portosystemic shunting , vasopressin

No full text is available. To read the body of this article, please view the PDF online.